Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906) - Top-Institutions - MDSpire

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)

  • By

  • Yan Zheng

  • Jiwei Wu

  • Lingdi Zhao

  • Yaxing Shen

  • Guanghui Liang

  • Keting Li

  • Quanli Gao

  • Wenqun Xing

  • May 7, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Sichuan Cancer Hospital
    Sichuan Cancer Hospital

    Chengdu, Sichuan

    Key Differentiators

    • Oncology

  • #2

    Journal of the National Cancer Institute
    Journal of the National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Oncology

  • #3

    UNC Lineberger Comprehensive Cancer Center
    UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

    Key Differentiators

    • Oncology

  • #4

    University Medical Center OWL, Campus Hospital Lippe, Detmold
    University Medical Center OWL, Campus Hospital Lippe, Detmold

    Detmold, North Rhine-Westphalia

    Key Differentiators

    • Oncology

  • #5

    University Hospital Magdeburg
    University Hospital Magdeburg

    Magdeburg, Saxony-Anhalt

    Key Differentiators

    • Oncology

Original Source(s)

Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)

  • by Yan Zheng, Jiwei Wu, Lingdi Zhao, Yaxing Shen, Guanghui Liang, Keting Li, Quanli Gao, Wenqun Xing

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...